CSCO heads into its Q3 fiscal 2026 earnings print — due after the close today — with a sharply changed backdrop from just a month ago: the stock is up 21% in 30 days, insiders sold in bulk last week, and the cost to borrow has tripled in a matter of days.
The most striking pre-earnings signal is in the lending market. Borrow costs tripled over the past week, climbing from roughly 0.29% to 0.87% — a 202% weekly move and the highest level in months. That spike coincides with a 7.4% rise in short interest over the same period, taking estimated short interest to around 63.3 million shares, or 1.6% of the free float. For context, that's up roughly 23% from a month ago. Availability remains loose in absolute terms, keeping the borrow market accessible to new short sellers, but the pace of change is notable. The short score has drifted higher all month, reaching 31.6 — still below the mid-range of the scale, but the trend is clearly upward heading into today's close.
Options positioning is not flashing the same caution. The put/call ratio eased to 0.70, slightly below its 20-day average of 0.73 and well below the 52-week high of 1.04. That's a modestly bullish tilt — call demand is running ahead of put demand. It contrasts with the short-side rebuild, suggesting the two camps are leaning in opposite directions. Some bears are adding exposure, while options traders are not hedging aggressively. That tension rarely resolves cleanly going into an earnings release.
Analyst sentiment has been broadly constructive but with clear ceiling awareness. Evercore ISI's Amit Daryanani raised his target to $110 on May 4 — the most recent action in the coverage — keeping an Outperform rating. JPMorgan lifted its target to $96 in April, also maintaining Overweight. The mean analyst price target is $89.54, which sits roughly 10% below where CSCO is trading today at $99.29. That gap is worth noting: the stock has rerated sharply above consensus targets on the back of its one-month rally, and the bulls are now making the case that AI infrastructure demand and hyperscaler contract wins justify a premium. The bear case centers on hardware revenue headwinds, the bumpy transition to recurring software, and M&A dilution risk. The dividend score ranks in the 98th percentile — a rare bright spot in the factor profile — while EPS momentum scores sit in the low 30s, below the sector midpoint.
The insider angle adds another layer. On May 8 — four days before today's session — seven executives sold shares simultaneously, including CEO Chuck Robbins ($1.52 million), President Jeetu Patel ($908k), and CFO Mark Patterson ($351k). Net insider activity over the past 90 days runs to a $10.3 million net sale across roughly 120,000 shares. Coordinated pre-earnings selling by this many senior executives is often tied to planned trading windows rather than directional conviction, but the clustering of names and timing, at a stock price near recent highs, adds context to the positioning picture. The stock traded at $96.57 when those sales went through — CSCO has added a further 3% since.
Cisco's last earnings print, in February, offers the clearest historical reference point. The stock fell 13% the day after results, and was still down 9% five trading days later — a sharp reaction that appears to have reset expectations significantly. That print marked the low end of the 30-day price range, and much of the current recovery has been built on the rebound from that selloff. Tonight's Q3 report is the first chance to determine whether February's miss was an inflection point or a false floor.
What to watch is whether the Q3 numbers — and crucially the forward guidance — are enough to hold the stock above the analyst consensus target zone. The gap between where analysts are currently set and where the market has priced CSCO is the arithmetic the results will need to bridge.
See the live data behind this article on ORTEX.
Open CSCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
